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Abstract: In assigning priorities, skin infectious diseases are frequently classified as minor when
compared to infectious diseases of high mortality rates, such as tuberculosis or HIV. However, skin
infections are amongst the most common and prevalent diseases worldwide. Elderly individuals
present an increased susceptibility to skin infections, which may develop atypical signs and symptoms
or even complicate pre-existing chronic disorders. When the skin fails to correct or inhibit the
action of certain pathogenic microorganisms, biomolecules endowed with antimicrobial features are
frequently administered topically or systemically to assist or treat such conditions. (1) Antibiotics,
(2) antimicrobial peptides, or (3) natural extracts display important features that can actively inhibit
the propagation of these pathogens and prevent the evolution of infectious diseases. This review
highlights the properties and mechanisms of action of these biomolecules, emphasizing their effects
on the most prevalent and difficult to treat skin infections caused by pathogenic bacteria, fungi, and
viruses. The versatility of biomolecules’ actions, their symbiotic effects with skin cells and other
inherent antimicrobial components, and their target-directed signatures are also explored here.
Keywords: pathogenic microorganisms; disruption of skin functions; biomolecule-based treatments;
mechanisms of action; prevalent skin infectious diseases
1. Introduction
Infectious diseases are emerging or re-emerging almost every year. They are a result
of the presence and growth of pathogens, such as viruses, bacteria, parasites, and/or
fungi, in the host organism, which can propagate between people. The type and extent of
damage inflicted by these microbial agents, which is intimately related to the production
and liberation of toxins that affect the regular tasks of each organ/system, could lead to
the appearance of specific clinical symptoms [1,2].
Since the beginning of the 20th century, infectious diseases have been classified as the
primary cause of death worldwide. Indeed, emerging infectious diseases are rising [2,3].
This trend is expected to continue, as newly evolved strains of pathogens emerge (multi-
resistant) and enter the human population without a proper fighting response being
available (e.g., severe acute respiratory syndrome (SARS) coronavirus). The increase in
the global population and its aging, the climate changes, and the facility of travel between
countries have all favored the emergence, evolution, and spread of these new pathogens [4].
Projection patterns of the evolution of this crisis have highlighted bacteria and viruses as
the most prevalent and concerning group of pathogens: the first due to their increasing
resistance to antibiotics and the second due to their high capacity to adapt to new hosts.
Skin infections are amongst the most common infectious diseases, ranked as the
fourth leading cause of human illnesses [5]. Both bacteria and viruses are responsible for
many serious, difficult to treat skin conditions. Fungi are also highly prevalent in skin
diseases. Skin infections present considerable threats to a person’s health, psychological
wellbeing, capacity to operate, and social involvement. In 2013, the socioeconomic burden
associated with skin diseases was estimated at USD 75 billion and USD 11 billion for
direct (healthcare expenses) and indirect (professional constraints) costs, respectively, in
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the USA [6]. As the population ages, the amount of people affected by skin conditions rises
proportionally. Tears in the skin integrity, which become more frequent with age as the
tissue loses its inherent elasticity and flexibility, are frequently inoculated by pathogens
that invade the dermis, causing skin infections. In many situations, the skin microbiota and
the antimicrobial factors produced by the various cell layers forming this tissue are capable
of fighting infections and preventing serious illnesses from evolving [7]. However, as the
pathogens evolve and mutate and the population ages, our inherent immune defenses
become compromised, being unable to effectively respond in a timely manner to their
action. Antimicrobial agents based on biological cues are, in many instances, essential to
overcome the shortcomings of our immune system and assist in the treatment of infectious
diseases [8]. Indeed, there are many antimicrobial biomolecules currently available to
fight pathogenic microorganisms that affect the skin. Antibiotics, due to their effectiveness
and accessibility, are among the most prevalent biomolecules to be used in treatments of
infectious diseases. They target the physiology or the biochemistry of the microorganism,
inhibiting their replication or inactivating specific functions, ultimately leading to their
death. Yet, due to the appearance and propagation of resistant microbial cells, therapies
for skin infections have become more challenging in the last twenty years [8,9]. New
biomolecules that impart specific cell functions or leave a smaller environmental footprint
are now raising more attention [10]. In the present work, an overview of the skin inherent
mechanisms of action against microbial cells and the alternative biomolecules that may be
used to assist in this action or surpass its limitations is presented. A complete description of
the most prevalent skin infectious disease traits and the possible biomolecules that can be or
are already being applied to treat such conditions is also provided, where special emphasis
is placed on natural-origin biomolecules. Generally, this publication reviews the most
recent research that explores the use of conventional or recently emerging biomolecules to
treat skin infections.
2. Skin: The First Line of Defense
The skin is humans’ largest and most exposed organ, offering protection against
the loss of endogenous compounds and external stimuli, including microbial invasion
(Figure 1). It forms 8% of the body weight and is subdivided into three major layers, the
epidermis which is the most superficial layer, the dermis located beneath the epidermis and
made mostly of connective tissues, and the hypodermis, which is a deeper, subcutaneous
tissue made from connective and adipose tissues [7,11,12].
The protective features of the skin vary across its regions and the age of the person, of-
ten generating conditions conducive for microbial growth in localized microenvironments
or exhibiting properties that impart a direct antimicrobial protection. Microorganisms
present along the skin are one of the largest communities of microbes in humans. In-
deed, the cutaneous microbiota contains bacteria, fungi, and viral communities. These
resident microbial species defend the host from pathogenic organisms by producing an-
timicrobial factors or stimulating cells to secret antimicrobial cues that prevent the growth
and proliferation of pathogens [14,15]. For instance, the skin-resident coagulase-negative
Staphylococci bacteria can produce toxins such as phenol-soluble modulins that attack more
harmful strains of bacteria, such as Staphylococcus aureus or Streptococcus pyogenes. Fur-
ther, they can work in symbiosis with the skin antimicrobial peptides (AMPs) to inhibit
pathogen colonization [7].
The epidermis operates as the first line of protection against microorganisms. It is
formed mostly of keratinocytes, whose phenotype and functions differ along the stratified
epidermis, the stratum corneum, the stratum granulosum, the stratum spinosum, and the
stratum basale. These keratinocytes express Toll-like receptors (TLRs) that trigger pathways
that maintain the host–microbial homeostasis [16]. These stratums offer resistance against
the penetration of most microbes by engaging with AMPs to fortify the integrity of the
skin barrier. Indeed, the epidermis is formed mostly of AMPs and lipids, both exhibiting
antimicrobial functions. AMPs are small peptide molecules that can both kill or inhibit
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microbial responses, limiting their growth. Their secretion is dependent on the conditions
of the skin (healthy or infected) [17]. Antimicrobial lipids, in their turn, are synthesized
and transferred to the surface of the skin during cell differentiation, being capable of
fighting Gram-positive and Gram-negative bacteria and increasing the expression of pro-
inflammatory cytokines to signal infections [18].
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At the dermis, fibroblasts produce collagen, elastin, and other extracellular s ecies
while still increasing the skin antimicrobial signals and, in this way, working as im-
u omodulatory cells [19]. The der is fibroblasts produce cytokines (interleukin (IL)-6,
IL-8, tumor ecr sis factor alpha (TNFα)), growth fact rs (vascular endothelial growth fac-
tor (VEGF), transforming growth fa tor beta 1 (TGFβ1)), and metallopr teinases (MMP-1)
that stimulate the adhesion and migration of immune cells, such as macrophages, mast
cells, leukocy es, and derm l dendritic cells [7]. Even though the antimicrobial action of
the derm s is not as important as that of the epidermis, the filtratio and recruitment of
immune ells to fight microbial pathogens that occur in this layer remain vital. T ese cells
provide additional a timicrobial defense by prom ting the liberation of large amounts of
cathelicidins, such as the AMP LL37 [20], that not only fight microbial coloniza io but
also stimulate keratinocyte proliferation and induction of angiogenesis. Indeed, in injured,
infected portions of the skin, the dermal fibroblasts and the epidermal keratinocytes work
in synergy to restore the skin barrier [19].
The hypodermis, also known as the subcutaneous layer, has a small but still very
important part to play in protecting the skin against microbial infection. The adipose
tissue of the subcutaneous layer can be subdivided into brown adipose tissue (BAT), white
adipose tissue (WAT), and “beige” adipose tissue [21]. The WAT, which can be found close
to hair follicles, altering in size as the hair grows, or underneath the dermal layer, is also
capable of producing cathelicidin AMPs and expands in size for a quick proliferation of
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adipocyte precursors. A recent study reported a causal relationship between the expansion
of adipose tissues and the hypodermis’s ability to protect against pathogenic cells [7,22].
This protective behavior inherent to all layers composing the skin relies on their cell
components or immune cells to which they impart a specific function, by meticulously
triggered pathways. Still, many pathogenic microbes can disrupt this specialized line of
defense, acting quickly against the human body and causing serious skin infections. To
overcome these shortcomings, antimicrobial biomolecules are frequently employed.
3. Biomolecules: Types, Properties, and Mechanisms of Action against Pathogens
Biomolecule is a loosely applied term to define biological materials derived from
living organisms (animals, plants, etc.) that exert important tasks in specific biological
phenomena. In infectious diseases, these biological cues are usually administered orally or
immobilized/incorporated within delivery systems for a local or systemic distribution [23].
In skin infections, three major classes of biomolecules with antimicrobial potential have
been identified: antibiotics, AMPs, and natural extracts.
3.1. Antibiotics
Antibiotics are considered the greatest clinical advance of the 20th century. They are
defined as chemical substances of microbial or synthetic origin endowed with antimicrobial
features that can treat infectious diseases. In order to be categorized as effective, antibiotics
should target intact elements of the bacterial cell wall, should reach their target in sufficient
amounts to elicit the desired effect, and should not undergo chemical alterations that may
hinder their effectiveness [24]. Antibiotic action can be classified as bactericidal, killing
bacteria, and/or bacteriostatic, preventing bacterial growth. Bactericidal antibiotics, such
as glycopeptides, beta-lactams, or fluoroquinolones, are often preferred to bacteriostatic
antibiotics in the treatment of skin disorders. These target the cell membrane of bacteria,
the cell wall biosynthesis of enzymes and other substrates, protein synthesis, or bacterial
nucleic acid replication, compromising the cell integrity and eventually leading to its
death [25]. Their specific structure and metabolism enable them to act against pathogenic
microbials with minimal side effects to mammalian cells [8].
Alterations in their performance may lead to bacterial resistance. This may occur
in response to: target modifications through mutation, decreased bacteria cell perme-
ability, reduced biomolecule influx or increased efflux, and degradation/deactivation of
the antibiotic molecules by means of enzymatic hydrolysis or chemical action [26]. The
overuse or misuse of these biomolecules has increased bacteria tolerance and the occur-
rence of antibiotic-resistant strains. Indeed, the spread of resistant bacteria has become
a growing public health concern, which renders lifesaving drugs less effective. For that
reason, alternative therapies based on AMPs or natural extracts are now gaining more
impact in patient care. Still, many efforts continue to be devoted to the development of
new and more effective drugs. Despite these drawbacks, antibiotics remain, to this day,
the main source of antimicrobial agents to fight bacteria-derived skin infections. Newer,
directed-spectrum antibiotics are, in fact, being design to circumvent these multidrug
resistance mechanisms [8,10].
3.2. Antimicrobial Peptides
AMPs are progressively gaining more focus as new therapies to treat skin infections.
Indeed, one of their pivotal roles in the skin is to guarantee its innate immunity. Their
significance in skin treatments became particularly noticeable when the release of cathe-
licidins during wound healing was uncovered and when the presence of β-defensins in
psoriatic scales was determined ample. AMPs not only impart antimicrobial effects but are
also involved in triggering immunological responses against microbial pathogens [27].
AMPs are oligopeptides formed of short sequences of amino acids. AMPs are low-
molecular weight biomolecules, cationic, and amphiphilic, which can be chemically syn-
thesized or secreted by procaryotic and eukaryotic cells (e.g., human skin). To date, all
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identifiable AMPs are categorized in one of four categories, according to their secondary
structure: β-sheet, α-helix, extended, and loop, with the first two configurations being
the most common. They target the lipopolysaccharide layer of microorganisms, which is
unique to them, hence expressing little effects against the low-anionic and cholesterol-rich
human eukaryotic cells. Moreover, due to their quick killing effect, resistance by microor-
ganisms is more difficult to cultivate. Depending on their target microbial agent, they can
be classified as antibacterial, antifungal, antiviral, or antiparasitic. In all cases, AMPs act
against the microbial cells by disrupting the membrane/wall/envelope integrity, inhibiting
proteins’, nucleic acids’, or other important compounds’ synthesis, or by permeabilizing
the microorganism and interacting with certain intracellular targets (Figure 2). One of
the most important features of AMPs is their ability to act against microbial cells using a
multi-hit strategy based on non-specific mechanisms of action, which tends to broaden
their spectrum of antimicrobial action even against multi-resistant pathogens [8,17,28,29].
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Recent studies have reported evidence of resistance mechanisms by pathogens against
naturally occurring skin AMPs. To overcome this obstacle, synthetic peptides are being
engineered. Research has shown that even very structurally similar peptides, synthesized
based on known natural structures, can impart completely different mechanisms of action
and even increase their range of targeted microbials. Another option has been to com-
bine different origin biomolecules, such as antibiotics with AMPs or AMPs with herbal
derivatives, to fight the enhanced microbial action of these resistant pathogens [31].
3.3. Natural Extracts
A substantial percentage of extracts collected from plants are claimed to display bene-
ficial results in infection control. To date, more than 12,000 secondary plant metabolites
have been isolated and identified, a number that represents less than 10% of the total possi-
bilities still available and to be discovered. These secondary metabolites act as antioxidants,
free radical-scavenging actuators, UV light absorbents, or protectors against potential
environment-derived attackers, namely, microorganisms. The palette of secondary metabo-
lites can be subdivided according to the chemical structure and synthetic pathways of their
active compounds. The major classes encompass (Figure 3): (1) phenolics, whose structural
motif is the phenol molecule, and which are produced by plants in response to bacterial
and fungal attacks against which they can generate non-specific interactions with proteins
or inhibit enzyme actions; (2) terpenes, whose structure includes one or more five-carbon
isoprene units, and which display toxicity that varies from lethal to completely comestible
depending on their ecological roles and may act against microbial pathogens by disrupting
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their membrane through lipophilic substances; and (3) alkaloids, which are heterocyclic
nitrogen complexes able to intercalate with microbial pathogens’ DNA, compromising their
normal functions [8,32]. Within the terpenes class, it is possible to find a very important
category of plant extracts that has been gaining considerable attention, namely, essential
oils (EOs). These are aromatic, volatile substances that can impart inhibitory or biocidal
effects against the replication of many microbial cells. EOs can permeate the cell membrane,
reducing the presence of important intracellular components by raising the local acidity,
which blocks the production of ATP and destroys genetic material [33]. Even though their
toxicity to human cells has been a major limitation to their generalized application in
medicine, with allergic reactions and skin irritation being the most recurrent side effects,
recent studies in which nano- and micro-delivery vehicles have been employed or the EOs
proportion has been reduced in combination with other antimicrobial substances have
been very promising, suggesting an optimistic future for EOs-containing strategies to treat
skin problems [10].
Pharmaceutics 2021, 13, x FOR PEER REVIEW 6 of 19 
 
 
Recent studies have reported evidence of resistance mechanisms by pathogens 
against naturally occurring skin AMPs. To overcome this obstacle, synthetic peptides are 
being engineered. Research has shown that even very structurally similar peptides, syn-
thesized based on known natural structures, can impart completely different mechanisms 
of action and even increase their range of targeted microbials. Another option has been to 
combine different origin biomolecules, such as antibiotics with AMPs or AMPs with 
herbal derivatives, to fight the enhanced microbial action of these resistant pathogens [31]. 
3.3. Natural Extracts 
A substantial percentage of extracts collected from plants are claimed to display ben-
eficial results in infection control. To date, more than 12,000 secondary plant metabolites 
have been isolated and identified, a number that represents less than 10% of the total pos-
sibilities still available and to be discovered. These secondary metabolites act as antioxi-
dants, free radical-scavenging actuators, UV light absorbents, or protectors against poten-
tial environment-derived attackers, namely, microorganisms. The palette of secondary 
metabolites can be subdivided according to the chemical structure and synthetic path-
ways of their active compounds. The major classes encompass (Figure 3): (1) phenolics, 
whose structural motif is the phenol molecule, and which are produced by plants in re-
sponse to bacterial and fungal attacks against which they can generate non-specific inter-
actions with proteins or inhibit enzyme actions; (2) terpenes, whose structure includes one 
or more five-carbon isoprene units, and which display toxicity that varies from lethal to 
completely comestible depending on their ecological roles and may act against microbial 
pathogens by disrupting their membrane through lipophilic substances; and (3) alkaloids, 
which are heterocyclic nitrogen complexes able to intercalate with microbial pathogens’ 
DNA, compromising their normal functions [8,32]. Within the terpenes class, it is possible 
to find a very important category of plant extracts that has been gaining considerable at-
tention, namely, ess ntial oils (EOs). These are aromatic, volatile substances that can im-
part inhibitory or biocidal effects gainst the replication of many mi robial cells. EOs can 
permeate the cell membrane, reducing the presence of important intracellular components 
by raising the local acidity, which blocks the production of ATP and destroys genetic ma-
terial [33]. Even though their toxicity to human cells has been a major limitation to their 
generalized application in medicine, with allergic reactions and skin irritation being the 
most recurrent side effects, recent studies in which nano- and micro-delivery vehicles 
have been employed or the EOs proportion has been reduced in combination with other 
antimicrobial substa c s have been very promising, suggesting an optimistic future for 
EOs-containing strategies to treat skin problems [10]. 
 
Figure 3. Major classes of natural extracts, phenolics, terpenes or terpenoids, and alkaloids (adapted 
with CC BY 4.0 license permission from [34]). 
  
Figure 3. Major classes of natural extracts, phenolic , terpenes or terpenoids, and alkal ( dapted with CC BY 4.0 license
permission from [34])
4. Prevalent Skin Infections and the Biomolecules Employed in Their Treatment
Skin infections can affect the skin layers and the inherent connective tissues. From the
neonate to the elderly, all of the human population can be affected by a wide spectrum of
skin diseases. In fact, when reaching 70 years old, nearly 70% of people will have had a
minimum of one skin condition in their life [35]. Bacteria, viruses, and fungi are amongst
the microbial pathogens responsible for the most frequent skin infections. In this section,
special attention will be placed on those dermatological illnesses that may benefit from the
action of conventional and/or new biomolecules in their treatments, namely, antibiotics,
AMPs, and natural extracts.
4.1. Atopic Dermatitis
Atopic dermatitis (AD) is a very frequent inflammatory disorder, highly pruritic, and
related to cutaneous hyper-reactivity to triggers present in the environment. It is identifi-
able by its poorly delineated erythema with edema, presence of vesicles, and, in acute states,
chronic weeping and skin thickening. There has been much debate as to whether AD is an
allergen-induced disease, or an inflammatory skin disorder found in combination with res-
piratory conditions. Regardless, investigations have demonstrated that AD is characterized
by an intricate etiology, with the stimulation of various immunologic and inflammatory
pathways. The prevalence of this condition is superior in children, with 10–20% of children
being affected compared to only 1–3% of adults [36]. Due to the industrial revolution of
the last three decades and the increased worldwide levels of pollution, these rates have
been continuously increasing, with effective treatments becoming highly demanded [37].
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AD is typified by dry skin and enhanced transepidermal loss of water. In AD, ce-
ramides, which are lipids present in the skin layers responsible for conserving the molecules
of water, are in deficit. Thus, the skin becomes more susceptible to irritants, conditioning
epidermal differentiation and prompting inflammatory responses. Allergens may also
trigger scratching of the skin which initiates the inflammatory cascade by releasing pro-
inflammatory cytokines from atopic keratinocytes [38]. In most patients with AD, as the
skin barrier becomes compromised, infections occur. S. aureus is the most prevalent microor-
ganism. It tends to aggravate AD conditions by producing toxins known as superantigens
that activate T cells and macrophages as the patients try to secret immunoglobulin E (IgE)
antibodies, specific against these molecules. They also induce corticosteroid resistance,
raising the severity of the patient’s condition. As S. aureus binds to the inflamed skin, its
innate response becomes compromised as this bacterium prevents the skin components
from producing AMPs necessary to protect the host from bacteria, fungi, and virus colo-
nization. For that reason, people suffering from AD have an enhanced tendency to develop
infections spread by herpes simplex or vaccinia viruses, for instance [36,39,40].
The conventional treatments for AD-related infections rely on the topical administra-
tion of antibiotics. Fusidic acid and mupirocin are among the most common. However,
recent reports have suggested that bacteria are starting to develop resistance. Alterna-
tively, formulations that combine gentamycin with corticosteroids have become more
popular in AD treatments. Another option is to employ antiseptics, such as triclosan or
chlorhexidine, in the form of emollients, which can significantly reduce colonization by
S. aureus without significant risks of skin sensitization. In cases where infection is caused
not only by S. aureus but also by S. pyogenes, systemic antimicrobials are preferable. Here,
amoxicillin/clavulanate or clindamycin antibiotics may be administered for a period of
3 to 7 days, even though gastrointestinal discomfort may occur. For longer periods, courses
of sulfamethoxazole/trimethroprin are recommended to prevent the development of mi-
crobial resistance [41]. In recent years, antibody- or cytokine-directed therapies have been
uncovered with successful outcomes in preventing T cell activation or the over-secretion of
cytokines and other mediators involved in AD. For instance, omalizumab, a humanized
monoclonal antibody selectively directed against circulating IgE, may block circulating
IgE’s interaction with the receptors of the basophils and the mast cells’ membrane, inhibit-
ing their activity, degranulation, and the liberation of different mediators responsible for
AD [42]. Even though these inhibitor-based therapies are very sought after, their interven-
tion against infection agents is considered minimal. Indeed, in many cases, additional or
secondary therapies are recommended. Herbal preparations are often used. Aloe vera, for
instance, has shown significant effects on AD skin lesions by reducing IL-5 and IL-10 levels
while fighting the presence of bacteria and fungi [43]. Cannabis sativa is also employed
to treat itchiness and relieve pain symptoms in AD. Using the oil from the seeds of this
plant, it is possible to strengthen the skin, increasing its resistance to bacterial, viral, and
fungal infections [44]. German chamomile (Matricaria recutita) has been used for centuries
to treat skin inflammations, including dermatitis. Topical chamomile ointments have even
been compared to hydrocortisone-containing formulations for their ability to reduce the
affected surface area or by improving sodium lauryl sulfate-induced contact dermatitis.
Their antimicrobial and anti-inflammatory performance has been attributed to the presence
of an essential blue oil in their composition, which is formed of sesquiterpene alcohol,
α-bisabolol, chamazulene, and flavonoids [45]. Tannin agents derived from black tea or
oak bark have also been suggested as effective in relieving acute weeping, or in soothing
inflammation and skin pruritus. They act by coagulating the protein regions in the cell
surface and the exudates, thus reducing absorbency and secretion, and by acting against
pathogenic microbials, reducing infection [46].
Flaws in the AMPs present in the skin barrier may contribute to the AD pathogenesis.
Indeed, LL37, hBD-2, and hBD-3 AMPs are frequently downregulated in lesions caused by
AD. In many instances, this reduced AMP expression is even triggered by the use of corti-
costeroids and calcineurin inhibitors applied topically [47]. To overcome such problems,
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many therapeutics targeting the skin microbiome and the inherent AMP expression have
been formulated with the goal of restoring skin homeostasis and, thus, overturning AD
symptoms. Smits et al. suggested the use of coal tar to activate the receptor aryl hydro-
carbon and, in this way, induce the secretion of AMPs derived from keratinocytes. Here,
as coal tar reduced the abundance of S. aureus and restored the microbiota composition to
healthier rates, the AMP levels in AD skin were also elevated, rendering the affected area
less prone to infection and inflammation [48].
4.2. Psoriasis
Psoriasis is an autoimmune chronic inflammatory skin condition in which localized
lesions, demarcated erythematous, and silver scaly plaques are often observed on the knees,
elbows, trunk, and scalp. It is characterized by an abnormal keratinocyte proliferation
and differentiation, increased dermal blood vessel formation with enhanced permeability
of wide-caliber vessels, and dermis invasion by several immune cells which increase the
inflammation mediated by cytokines, including tumor TNFα, interferon-γ (IFN-γ), and
various ILs [49]. The prevalence of this skin infectious disease has been rising over time,
now affecting 2–3% of the global population, with 0.5–11.4% being adults and 0–1.4%
being children [50]. In patients with psoriasis, the life cycle of the skin reduces from 30 to
1.5–3.0 days, which facilitates the appearance of localized lesions [51]. Dry, cracked skin
and irritation are also very common. Psoriatic areas may vary in size from a few spots of
dandruff-like scaling to large outbreaks that spread significantly across the body. Various
forms of psoriasis have been identified: (1) plaque, the most frequent, characterized by
red skin patches and silvery scales that predominate on the elbows, the lower back, the
knees, or the scalp; (2) nail, which affects fingernails and toenails, resulting in pitting,
atypical nail development, and discoloration; (3) guttate, which is primarily detected
in children and young adults and is triggered by bacterial infections; (4) inverse, which
causes the appearance of smooth red skin patches on intimate regions (e.g., groin, breasts,
or buttocks) and may be aggravated with the friction and sweat sensed on these areas;
(5) pustular, which is more rare and is characterized by the appearance of pus-filled lesions;
(6) erythrodermic, the least common, which affects the entire body of the patient, covering
it with a red, peeling rash; and (7) arthritis, which affects the patient’s joints and may cause
stiffness or progressive joint damage [52].
Many microorganisms have been associated with the initiation and/or worsening
of psoriasis, regardless of the type, including bacteria (S. pyogenes, S. aureus), fungi
(Malassezia, Candida albicans), and viruses (papillomaviruses, retroviruses, endogenous
retroviruses) [53]. The most significant effect has been that of the bacterium S. pyogenes,
evidenced in both acute and chronic psoriatic patients. This pathogen is mostly associated
with the guttate form of psoriasis. Here, superantigens or T cell-activating toxins generated
by this bacterium can bind to the T cell receptors, inducing the manifestation of a skin
homing receptor, the cutaneous lymphocyte antigen, which may trigger an autoimmune re-
action on the skin [54]. Near 60% of psoriatic patients present lesions colonized by S. aureus.
The presence of toxin-positive S. aureus on patients’ skin was found to have a significant
impact on the dimensions of the affected area and the severity of the disorder [55]. In the
case of fungi, Malassezia tends to occupy the outermost regions of the stratum corneum rich
in sebaceous glands, frequently being found associated with lesions present on the chest,
back, and scalp. They act by upregulating keratinocyte expression, which then results
in a hyperproliferation and cell migration of the epidermis [52,56]. The mechanism by
which C. albicans exacerbates psoriasis is not yet known. However, a correlation with an
increased number of this pathogenic yeast’s presence in feces of psoriasis patients has been
established. It is suspected that C. albicans may produce superantigens just like S. pyogenes
or S. aureus, stimulating T cell activation and, thus, leading to an increased severity of the
psoriatic lesions [52].
Currently, psoriasis does not have a cure. Yet, many strategies have been designed to
try and relieve the patient symptoms and prevent the evolution of psoriasis-related signs.
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Conventional topical medications incorporate corticosteroids, vitamin D3, retinoids, cal-
cineurin inhibitors, coal tar, dithranol, and emollients, while systemic therapies frequently
resort to immunomodulators (cyclosporine) and retinoids (acitretin). Corticosteroids are
considered the gold standard for psoriasis treatment. Once applied, corticosteroids can
bind to the glucocorticoid receptors in the cells’ cytoplasm, increasing the formation of
lipocortin, which is responsible for inhibiting the phospholipase A2 activity and the forma-
tion of IL-1. These actions wield anti-inflammatory, immunosuppressant, anti-proliferative,
and anti-mitogenic impacts. However, they may also affect the epidermis, rendering the
skin photosensitive, delaying wound healing, and causing ulceration or even atrophy of
the affected areas [57]. To prevent such events, emollients and moisturizers, which exhibit
anti-inflammatory effects, prevent microbial invasion, and reduce transepidermal water
loss, may be used as adjuvant actuators. The use of these antibiotics in psoriasis has been
prompted mostly by the presence of streptococci bacteria in different forms of the disease.
They act against the bacteria by preventing the colonization of pathogens along the lesions
or by targeting specific factors associated with their infectious potential. Even though they
remain a highly effective choice, they may also hinder skin healing or even exacerbate
the condition (Table 1) [58]. In recent years, biologics, which are biomolecules that target
the immune or genetic mediators in a pathophysiologic event, have been used to target
T cells or block the action of TNFα and IL actuators and, in this way, reduce the inflam-
matory response in psoriasis. The USA Food and Drug Administration (FDA) endorsed
the first biologics in 2003, namely, alefacept and efalizumab, but since then, many more
have progressed successfully through clinical trials and have reached the market. These
biomolecules have been considered more effective than corticosteroids as they suppress the
activated local immune response. However, their long-term use may increase the risk of
uncontrolled infections [51,59]. Recent research has demonstrated that, by combining these
biologics with metabolites present in vitamins, it is, indeed, possible to overcome such prob-
lems. For instance, the use of IL-17 inhibitors, which modify the cytokine pathways, may
also increase the risk of fungal infections caused by Candida spp. Vitamin A is a fat-soluble
vitamin involved in a variety of metabolic and physiologic activities but also works as a
host-protective effector against bacterial, viral, and yeast infections. Since IL-17 is engaged
in the inflammatory reaction responsible for triggering and sustaining psoriatic disease,
and knowing that TH17 cells specific to C. albicans produce IL-17, combinations of inhibitors
of this cytokine with antimicrobial molecules are seen as a promising solution [60].
For many years, natural extracts have been used to treat infected skin lesions in psori-
asis, mostly as a complementary therapy. Capsaicin (Capsicum frutescens) was determined
to hamper phorbol ester-stimulated initiation of transcription factors NF-κB and AP-1,
which then resulted in a significant decrease in scaling and erythema in moderate to severe
psoriasis patients [61]. Curcumin behaves similarly, being capable of suppressing the
phosphorylase kinase activity and even imparting antimicrobial and antioxidant effects
onto the affected areas. In the form of nano-emulsions or while microencapsulated, its
action is even more effective, reducing the yellow staining of the skin derived from its
topical administration [62]. EOs can provide soothing effects to the affected areas of the
skin and even effectively irradiate pathogens. Tea tree oil (TTO), rose geranium oil, and
lavender oil are all endowed with anti-inflammatory features as well as antibacterial and
antifungal properties. Marine sponges, such as Dysidea avara, are also known to effectively
inhibit inflammatory biomarkers, such as TNFα, and to suppress the action of keratinocytes.
Most importantly, they are effective antiviral biomolecules and may display moderate
antibacterial activities [63].
4.3. Herpes Simplex and Zoster
Herpes simplex viruses type 1 and type 2 (HSV1 and HSV2) and varicella-zoster
virus (VZV) are neurotropic pathogenic viruses found in humans. Both HSV and VZV
are affiliated to the herpesviridae DNA viruses. The first is frequently detected in the
labial skin of the mouth (HSV1) or genitalia (HSV2), and the second is characterized by
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cutaneous eruptions along the skin filled with pus that tend to rupture and scab before
healing. HSV1 is mostly transmitted by oral–oral contact but may also be transmitted
by oral–genital contact. Oral herpes infection is mostly asymptomatic. However, those
that exhibit symptoms tend to experience painful blisters or open sores in or around the
mouth. HSV2 is mostly transmitted during sex, through genital contact. As with oral
herpes, people affected by HSV2 are often asymptomatic, and those exhibiting symptoms
reveal the presence of blisters or open sores around the genitals or anal region. Both HSV
and VZV share specific identifiable traits that influence their infective sequence in the body:
they start by acting on the mucocutaneous regions, which work as an entryway portal of
infection, and then may be transported towards the dorsal root ganglia, where they are
kept in a latent form until the virus is activated. Even though primary infection occurs in
the first twenty or thirty years of a person life’s, revival of the virus may still take place in
advanced ages [64,65].
Table 1. Antibiotics most frequently employed to treat psoriasis, their targeted bacteria, mechanisms of action, and effects
on the condition (adapted from [58]).










Vancomycin G(+): enterococci, streptococci,S. aureus (MRSA), S. epidermidis.
Dysregulates gut and skin
microbiota; activation of T cells.









inhibits the action of the
cytokines TNFα, IL-6, and IL-8.
Improves plaque psoriasis.
Azithromycin
G(+): streptococci, S. aureus.
G(−): N. gonorrhoeae, Haemophilus







G(+): streptococci, S. aureus, Listeria
monocytogenes, Bacillus anthracis, etc.
G(−): bacilli spp.
Increases the photosensitivity of











secretion of IL-6 and IL-10.
Improves plaque psoriasis.
Abbreviations: G(+)—Gram-positive;
G(−)—Gram-negative; MRSA—methicillin-resistant S. aureus.
Antivirals such as acyclovir, famciclovir, and valacyclovir are very effective in treating
HSV. They act by preventing viral replication by means of inhibiting DNA polymerase
action in infected cells. The application of corticosteroids as secondary or additional thera-
pies remains contentious; however, when HSV is associated with encephalitis conditions, a
high dose of steroids may be recommended [64]. Melissa officinalis oils presented to HSV1
lesioned areas in the form of balms have been shown to significantly act on patients by
reducing the size of the ulcerations and the healing time. Here, tannin and polyphenols
have been indicated as responsible for the antiviral effects of these balms [66]. These
same antivirals may also be used to treat or prevent HSV2. However, a prophylactic and
corrective anti-HSV2 vaccine is usually recommended.
VZV is mostly a disorder of older people, and its appearance may be triggered by
disorders such as diabetes mellitus, spinal anesthesia, malignancies, and conditions associ-
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ated with immune suppression (e.g., AIDS) [64]. The therapeutic approach is similar to
HSV, resorting mainly to the antivirals acyclovir, famciclovir, and valacyclovir, the last two
being preferrable due to their superior pharmacokinetic reports and easier dosing routines.
Alternatively, the antiviral drugs brivudine and foscarnet may also be employed [67]. The
natural extracts Capiscum frutescens and hibiscus have been reported to reduce localized
pain generated by ulcers, while glycyrrhizin-derived products were reported to hinder
the in vitro propagation of varicella zoster [68,69]. At the moment, no in vivo studies have
been conducted using these natural components.
4.4. Acne
Acne vulgaris is a very frequent skin condition. It often appears in oily regions of
the body, namely, the face, back, and trunk. Acne vulgaris is considered an inflammatory
disease of pilosebaceous follicles, affecting over 85% of the youngster population. It is
caused by a heightened sebum formation, hypercornification of the pilosebaceous duct,
abnormal behavior of the microbial skin flora with colonization of the duct with Cutibac-
terium acnes, and an irregular inflammatory response. Even though acne is not considered
an infectious disease per say, four key microorganisms can be isolated from the skin of
patients suffering from this disorder, namely, C. acne, Cutibacterium granulosum, Staphy-
lococcus epidermidis, and Malasezia furfur. These are normal skin commensals that tend to
proliferate very quickly during puberty, very often being responsible for the development
of acne. Indeed, the hypercolonization of the sebaceous follicle by C. acnes has been known
to increase acne-related inflammation by inducing immunological reactions, including the
upregulation of cytokine expression by its extracellular biproducts, the sebum free fatty
acids metabolized by the triglycerides. Contrary to the other microbials, S. epidermidis is
regularly engaged in superficial infections within the sebaceous unit [70–72].
For many years, topical retinoids, benzoyl peroxide, and topical/systemic antibiotics
have been used to treat this condition. Lymecycline, erythromycin, and oxytetracycline are
among the most common antibiotic strategies [73]. However, C. acnes has been revealing
increased resistance to these standard therapies. It is not yet clear if the resistance to
the action of the antibiotics is indeed related to the presence of this microbial cell or the
combination of various pathogens with endogenous unregulated factors. There have been
reports showing variations in response to antibiotics from C. acnes colonies within the same
culture. Differences between C. acnes strains with the ability to form biofilms resistant to
antimicrobials have also been described. For instance, beta-lactam antibiotics are ineffective
against acne, but quite effective against in vitro cultures of C. acnes [74]. As in acne vul-
garis, innate AMPs are upregulated in keratinocytes and sebocytes, which may exacerbate
the inflammatory response, and alternative treatments resorting to AMPs have become
excellent candidates to overcome the limitations faced by antibiotic-based therapies. AMPs
can inhibit the growth of C. acnes while increasing anti-inflammatory cytokine secretion.
The ability of peptides derived from granulysin to decrease the presence of acne in the
body, by displaying bactericidal and anti-inflammatory effects against C. acnes, has proven
just that [75]. Further, the cecropin A-magainin 2 hybrid analog P5 AMP can bind to lipote-
ichoic acid, lowering C. acnes-triggered TLR2 upregulation in keratinocytes and inhibiting
microbial growth [76]. Analogous findings were achieved with melittin peptides [77]. De-
signed peptides which are chemically synthesized are another option to modulate immune
responses and impart antibiotic properties against pathogens. Woodburn et al. uncovered
five new AMP sequences with bactericidal effectiveness against C. acnes commercial strains
and clinical isolates. Their specificity for eliminating multidrug-resistant C. acnes over
mammalian cells was also evidenced. Moreover, the topical administration of the most
successful designed AMP was seen to eliminate infection [78].
Oxidative stress is another biproduct of the sebum produced from damaged follicular
walls of sebaceous glands in acne. This is initiated by reactive oxygen species (ROS) respon-
sible for the skin irritation associated with acne infection. As most synthetic antioxidant
compounds tend to aggravate this situation, acting on the skin microbiota, plant-derived
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molecules endowed with antimicrobial features have become an important alternative.
Vora et al. reported the potentiality of methanolic extracts of Rosmarinus officinalis, Acacia
nilotica, and Azadirachta indica to fight infections caused by C. acnes while highlighting their
antioxidant mechanisms [79]. Resveratrol, extracted from grape seeds, has been incorpo-
rated in a carboxymethylcellulose-based gel to serve as a mask with equal purposes [80].
Rhodomyrtus tomentosa, from the Myrtaceae family, contains various phytochemical com-
pounds (ellagitannins, stilbenes, anthocyanins, flavonols, and phenolic acids) with potent
antioxidant, anti-inflammatory, and antimicrobial properties. Recent reports have shown
that this natural extract possesses microbiota-regulating agents, which reduce retentional
and inflammatory acne lesions while decreasing the abundance of C. acnes bacteria [81].
Similar observations were made with TTO and rosemary EOs. Data reported bacteriostatic
and bactericidal activity of these two natural compounds against antibiotic-resistant acne
clinical isolates [82]. The synergistic effect between EOs has also been examined by Bun-
rathep et al., who reported an optimal ratio concentration between citronella, lemongrass,
and patchouli EOs for an effective antibacterial action against C. acnes and S. epidermidis [83].
4.5. Tinea
Tinea is the name of a group of superficial skin infections caused by fungi, namely, by
dermatophytes (filamentous fungi). Depending on the affected region, different designa-
tions may be employed: tinea corporis, which affects the trunk, neck, arms, and legs; tinea
cruris, which involves the groin region; tinea pedis, commonly found on the feet; tinea
faciei, found on the face; tinea capitis, frequently found on the scalp; and tinea manuum,
which can be detected in the hands. Regardless of the type, the most common dermato-
phytes acting to cause infection belong to the genera Trichophyton, Epidermophyton, and
Microsporum and have been classified based on their spread mechanism in anthropophilic
(human), zoophilic (animal), and geophilic (soil) environments [84,85]. Dermatophytes are
capable of digesting keratinized tissues into oligopeptides or amino acids by proteases,
serine-subtilisins, and fungolysin. They also reveal potent immunogenic actions by impair-
ing the functions of Th17 cells and reducing secretion of IL-17 and IL-22, thus rendering
infections more persistent. In microenvironments of the body characterized by excessive
heat, alkaline pH, maceration, or a high relative humidity, proliferation of these pathogens
increases significantly [86].
Most treatments for dermatophyte-induced infections resort to topical and oral an-
tifungal preparations. The most employed topical antifungals are based on clotrimazole,
ketoconazole, miconazole, naftifine, and terbinafine formulations. Oral therapies are re-
quired in more widespread infections in which topical treatments are infective and resort
to terbinafine, itraconazole, fluconazole, or griseofulvin courses [85]. Yet, as topical media-
tions tend to present superior pharmacokinetics, combinations of topical and oral therapies
have been highlighted as preferrable in imparting better microbial clearance. Shah et al.
proposed the combination of terbinafine, a drug responsible for inhibiting the enzyme
squalene epoxidase and, consequently, ergosterol synthesis, with ciclopirox olamine, a
topical hydroxypyridone derivative which acts through the chelation of polyvalent metal
cations, inhibiting metal-dependent enzymes. Their combination was seen to be very
effective against tinea corporis and tinea cruris infections, without conveying detectable
side effects to the patients [87].
AMPs are not as common as antifungals in the fight against dermatophyte-derived
infections. However, there have already been reports on the effective use of psoriasin,
an AMP isolated from psoriatic lesions, against Trichophyton mentagrophytes, Microsporum
canis, and Epidermophyton floccosum fungi. This compound is capable of interfering with
zinc homeostasis, whose sequestration could result in an important antimicrobial mecha-
nism [88]. Synthetic AMPs have also been uncovered. Lima et al. reported the synthesis of
six synthetic AMPs with capability to either be used as models for novel antidermatophytic
drugs or as complementary therapies for pre-existing ones. It was seen that the six AMPs
were capable of reducing the growth of T. mentagrophytes and Trichophyton rubrum fungi by
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up to 95%, by causing severe damage to their hyphal morphology, namely, by disturbing
the cell wall, inducing content leakage and consequent cell lysis. Most importantly, these
AMPs were far more effective than the conventional antifungals griseofulvin and itracona-
zole [89]. Alternative strategies by means of plant extracts have also been used in successful
topical therapies. Sixty-five single EOs and twenty-one blends have been examined for
their mechanisms of action against dermatophytes. From those, cassia, cilantro, cinnamon,
thyme, and oregano EOs were found to be the most effective when used individually,
while synergistic performances were observed when combining oregano, cilantro, cassia, or
cinnamon, and with rosa and cassia formulations [90]. Macrocarpal C, extracted from the
leaves of Eucalyptus globulus Labill, has shown a significant effect against T. mentagrophytes
and T. rubrum fungi [91]. The crude leaf extract of Tetradenia riparia was examined against
three clinical isolates of dermatophytes, T. tonsurans, T. mentagrophyte, and M. audouinii, re-
vealing significant antidermatophytic activity [92]. Similar effects were obtained with calyx
leaves of Hibiscussabdariffa L. when examined against the same pathogens, demonstrating
great inhibitory performance against skin isolates due to their alkaloid, tannin, kalekoside,
and phenol components [93].
4.6. Wound- and Burn-Derived Infections
From a microbial viewpoint, the main purpose of integral, undamaged skin is to
avoid the incursion and colonization of underlying tissues. However, the exposure of
the subcutaneous layers of the skin following loss of integrity may provide conditions
conducive to microorganisms’ growth. In acute wounds, the presence of microbial cells is
not significant, with the healing cascade being capable of progressing without constraints.
In chronic wounds, however, the presence of polymicrobial and/or resistant infection
agents associated with a persistent inflammatory state frequently demands complementary
antimicrobial therapies. Often disguised as a comorbidity condition, chronic wounds have
been classified as a silent epidemic that affects a large fraction of the world population,
with significant economic costs associated [12,17,20]. Similarly, burn wounds represent a
susceptible site for opportunistic pathogens’ colonization. Indeed, it is estimated that most
registered deaths following burn injuries are correlated with infections rather than osmotic
shock or hypovolemia. As microorganisms bind to these wounds, they start penetrating
the burn eschar, quickly invading viable subeschar tissue and rendering it infected [94].
Non-healing wounds such as chronic or large-area burns may impair the physiological
functions of the skin and spark morbidity or mortality risks. A major advance in treating
these infected wounds has been the understanding that the mere presence of microorgan-
isms is less important than their growth rate. Here, S. aureus and Pseudomonas aeruginosa
bacteria have been identified as the most recurrent pathogens. S. aureus is typically located
in the skin superficial layers, while P. aeruginosa is spotted in the innermost regions of the
wound bed [95,96]. By controlling infection, antimicrobial agents reduce the tendency for
conversion of partial thickness wounds into full thickness wounds. Topical antimicrobial
agents based on silver compounds, such as silver nitrate, silver sulfadiazine, mafenide
acetate, or nanocrystalline silver, are frequently employed to prevent the spread of bacteria
and even fungi (e.g., C. albicans) in infected wounds. The silver inhibitory effect results
from its powerful interaction with the thiol radicals found in the respiratory enzymes of
the microbial cells [97]. Mupirocin, an antibiotic produced from the fermentation process
of Pseudomonas fluorescens, has also been highlighted as a powerful inhibitory effector
against Gram-positive skin flora bacteria, such as coagulase-negative staphylococci and
S. aureus, including MRSA [98]. Nystatin, an antibiotic produced from Streptomyces nour-
sei, is considered a potent antifungal agent, whose action arises from its connection to
the cell membrane sterols of fungi, imparting significant effects on wounds colonized by
C. albicans [99]. Antiseptic agents such as povidone, cadexomer iodine, chlorhexidine,
polyhexamethyl biguanide, and honey have also been applied to treat chronic wounds
both to reduce inflammation and/or fight infections [17].
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The healing significance of natural AMPs in wounds has been extensively ana-
lyzed [96]. Yet, in infection-directed therapies, only those AMPs that exhibit reduced
cytotoxicity, great stability in microbial-colonized environments, and a broad antimicrobial
spectrum of action can be used. The natural-origin peptide LL37 has shown significant
effects against S. aureus and S. epidermidis bacteria, above conventional antibiotics (e.g.,
vancomycin), while functionalized onto poly(vinyl alcohol)/cellulose acetate dressings [20].
The novispirin G10 peptide revealed a quick action against P. aeruginosa on partial thick-
ness burns before being inactivated by proteases [100]. In its turn, PXL150 demonstrated
powerful antimicrobial actions by altering the potential of the S. aureus membrane and
quickly eliminating P. aeruginosa bacteria [101]. Dual AMP combinations have also been
attempted with pexiganan and nisin peptides. Gomes et al. reported their symbiotic effect
against co-cultures of S. aureus and P. aeruginosa clinical strains and disclosed the need for
smaller AMP concentrations, when in blends, to obtain effective outcomes [102].
Natural extracts have been considered, for years, as important players in the treat-
ment of infected wounds [103]. Aloe vera is perhaps one of the most used as it decreases
burning, itching, and scarring in many skin infectious diseases. Salicylic acid present in
its composition is known to display analgesic and anti-inflammatory effects by hindering
prostaglandin production. This effect may be a result of the immunomodulatory assets
of the gel polysaccharides present, namely, the acetylated mannans. Aloe vera also dis-
plays significant bactericidal and fungicidal effects [104]. Resveratrol, commonly found
in grape seeds, and a silent information regulator 1 (SIRT1) agonist, has been known
to improve endothelial functions and to possess a strong proangiogenic profile, highly
effective against diabetic chronic ulcers [105]. Thymol and tyrosol derived from EOs have
been proposed as potential additives to antimicrobial dressings by providing both bacteri-
cidal and anti-inflammatory effects [106]. Encapsulated EOs are very common in wound
healing [107]. For instance, peppermint EOs loaded into nanostructured lipid carriers have
demonstrated important antibacterial effects against a wide range of pathogenic strains,
aside from increasing wound contraction, fibroblast penetration, collagen deposition, and
re-epithelialization [108]. In another study, cinnamon leaf oil, clove, and cajeput EOs em-
bedded within wet-spun biodegradable microfibers were seen to act more quickly against
S. aureus than the ampicillin antibiotic [109].
5. Conclusions
The response of the skin to microbial pathogen invasion is a highly coordinated phe-
nomena that encompasses all skin layers and, in many cases, the skin microbiota. At a
molecular level, the microbiota-produced antimicrobial factors, the host AMPs, and the
antimicrobial lipids play a crucial role in fighting pathogenicity. However, the skin, on its
own, is not always effective in fighting the penetration of bacteria, fungi, or viruses, and, as
such, serious skin infectious may occur. Antimicrobial biomolecules, including antibiotics,
AMPs, or plant extracts, may assist in overcoming this limitation. Their propensity to both
control infections, eliminating pathogenic microorganisms, and be involved in important
anti-inflammatory actions has rendered these biomolecules essential in medicine. Indeed,
while inducing infection-solving immunity and regulating innate immunity, these antimi-
crobial biomolecules dampen and potentially damage pro-inflammatory reactions. Their
varied roles and synergisms with innate substrates have been highlighted in the treatment
of many skin infectious diseases. This review explored conventional and more recent
therapeutic strategies based on active biomolecules to treat some of the most recurrent
skin infections. Even though many do not consider skin infections a global problem and
do not demand urgent solutions, modern research continues to dedicate its resources to
finding more effective strategies that present the smallest impact on human health or our
natural reserves.
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65. Jevšnik, M.; Lusa, L.; Uršič, T.; Biškup, U.G.; Petrovec, M. Detection of herpes simplex and varicella-zoster virus from skin
lesions: Comparison of RT-PCR and isothermal amplification for rapid identification. Diagn. Microbiol. Infect. Dis. 2020, 115015.
[CrossRef]
66. Vanti, G.; Dourdouni, V.; Lazari, D.; Panagiotidis, C.; Ntallis, S.; Litsiou, S.; Patsoura, C.; Piazzini, V.; Risaliti, L.; Bergonzi, M.
Melissa officinalis essential oil loaded glycerosomes: Preparation and in vitro activity evaluation against herpes labialis (HSV-1).
Planta Med. 2019, 85, SL-YRW.
67. Yang, Q.; George, M.G.; Chang, A.; Tong, X.; Merritt, R.; Hong, Y. Effect of herpes zoster vaccine and antiviral treatment on risk of
ischemic stroke. Neurology 2020, 95, e708–e717. [CrossRef] [PubMed]
68. Fatima, G.; Jabeen, A.; Siddiqui, S.A.; Khalid, M. A review on Glycyrrhiza glabra L.(As.l al-Sūs) with unani perspective and
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